North America Anti-Infective Agents Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- anti infective agents market
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the anti infective agents market
North America anti-infective agents market highlights
- The North America anti-infective agents market generated a revenue of USD 50,451.9 million in 2025.
- The market is expected to grow at a CAGR of 1.4% from 2026 to 2033.
- In terms of segment, antivirals was the largest revenue generating type in 2025.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 50,451.9 million |
| Market revenue in 2033 | USD 54,553.5 million |
| Growth rate | 1.4% (CAGR from 2026 to 2033) |
| Largest segment | Antivirals |
| Fastest growing segment | Antifungals |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, North America region accounted for 37.7% of the global anti-infective agents market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 44,829.0 million by 2033.
The North America anti-infective agents market is experiencing steady growth, driven by rising cases of infectious diseases, hospital-acquired infections, and a growing elderly population susceptible to infections. HIV.gov reports that approximately 31,800 people acquired HIV in the U.S. in 2022.
Additionally, in the same year, 37,981 individuals aged 13 and older received an HIV diagnosis across the U.S., including its six territories and freely associated states. Innovations in the field, especially in response to antibiotic resistance, have spurred demand for new antibiotics, antifungals, antivirals, and other anti-infective treatments.
No credit card required*
Publish Date: Jun 25, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti Infective Agents Market
Anti Infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Mankind Pharma | View profile | 10001+ | New Delhi, Delhi, India, Asia | www.mankindpharma.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
North America anti infective agents market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 52.11% in 2025.
Horizon Databook has segmented the North America anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
The North America anti-infective agents market is experiencing steady growth, driven by rising cases of infectious diseases, hospital-acquired infections, and a growing elderly population susceptible to infections. HIV.gov reports that approximately 31,800 people acquired HIV in the U.S. in 2022.
Additionally, in the same year, 37,981 individuals aged 13 and older received an HIV diagnosis across the U.S., including its six territories and freely associated states. Innovations in the field, especially in response to antibiotic resistance, have spurred demand for new antibiotics, antifungals, antivirals, and other anti-infective treatments.
- North America Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antibacterials
- Antivirals
- Antifungals
- North America Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Topical
- Others
- North America Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to anti infective agents market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
- Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America anti infective agents market, including forecasts for subscribers. This continent databook contains high-level insights into North America anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Anti-Infective Agents Market, 2021-2033 (US$M)
North America Type - Anti-infective Agents Market Statistics, 2025 - 2033 (US$M)
